MiMedx Group: receives FTC second request in Sanara merger

What happened

• MiMedx Group, Inc. reported that it previously entered into an Agreement and Plan of Merger with Sanara MedTech Inc. and Mustang Merger Sub, Inc., a wholly-owned subsidiary of MiMedx, under which Merger Subsidiary will be merged with and into Sanara, with Sanara surviving as a wholly-owned subsidiary of MiMedx.
• On Oct 15, 2026, MiMedx and Sanara each received a request for additional information and documentary materials (a "Second Request") from the Federal Trade Commission in connection with the FTC’s review of the merger. The 8-K states that the Second Request extends the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act until 30 days after the parties have substantially complied with the Second Request, unless that period is extended by the parties or terminated earlier by the FTC. The filing says completion of the merger remains subject to expiration or termination of that waiting period and satisfaction or waiver of other closing conditions.

Key details

• Date of Second Request: Oct 15, 2026.
• Parties named in the filing: MiMedx Group, Inc.; Sanara MedTech Inc.; Mustang Merger Sub, Inc.
• Effect under HSR Act: waiting period extended until 30 days after substantial compliance, unless extended or terminated earlier.
• The filing notes a Form S-4 registration statement was filed with the SEC and that the final prospectus has been mailed to Sanara stockholders; documents are available on sec.gov and the companies’ investor websites. The filing also includes forward-looking statements and lists related risk factors, including those in MiMedx’s Form 10-K filed Feb 25, 2026.

Why it may matter

• This report is filed under Item 8.01 "Other events" and describes the receipt of an FTC Second Request under the HSR Act and the procedural extension of the HSR waiting period referenced in the merger agreement. A filing does not show why the insider traded or why the company acted.